• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

    6/11/24 7:00:00 AM ET
    $ASPI
    $ATRA
    $CIA
    $CLNN
    Major Chemicals
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASPI alert in real time by email

    MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    For updates, follow us on Twitter

    Sponsors:

    QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions

    (844) 485-8200

    Sales@QuoteMedia.com

    QuoteMedia.com

    ProCore Advisory - Unleashing the power of strategic investor relations for public and pre-IPO companies

    (832)-847-1327

    pierre@procoreadvisory.com

    www.procoreadvisory.com

    Day 1

    June 12, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Perfect Corp. (NYSE:PERF)

    Keynote speaker: Louis Chen, EVP, CSO

    9:40 - 10:10

    Intellabridge Technology Corporation (OTCQB:KASHF) (CSE:KASH)

    Keynote speaker: John Eagleton, CEO

    10:15 - 10:45

    Pulsar Helium, Inc.'s (OTCQB:PSRHF) (TSXV:PLSR)

    Keynote speaker: Thomas Abraham-James President / CEO

    10:50 - 11:20

    Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

    Keynote speaker: Mr. Quang X. Pham, Chairman & CEO

    11:25 - 11:55

    LogicMark, Inc. (NASDAQ:LGMK)

    Keynote speaker: Ms. Chia-Lin Simmons, CEO

    12:00 - 12:30

    Unusual Machines, Inc. (NYSE:UMAC)

    Keynote speaker: Allan Evans, CEO

    12:35 - 1:05

    SeaStar Medical Holding Corporation (NASDAQ:ICU)

    Keynote speaker: Eric Schlorff, President / CEO, Director

    1:10 - 1:40

    Diakonos Oncology, Inc.

    Keynote speakers: Jay Hartenbach, COO, & Anthony Baldor, CFO & Head of Business Development

    1:45 - 2:15

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    2:20 - 3:00

    Clene Inc., (NASDAQ:CLNN)

    Keynote speaker: Rob Etherington, President / CEO, & Morgan Grown, CFO

    3:05 - 3:15

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    3:20 - 3:30

    SenesTech, Inc. (NASDAQ:SNES)

    Keynote speaker: Joel L. Fruendt, President, CEO, & Director

    3:35 - 4:05

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    Day 2

    June 13, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    FBR, Ltd. (OTCQB:FBRKF) (ASX:FBR) 

    Keynote speaker: Michael John Pivac, CEO & Managing Director

    9:40 - 10:10

    Huize Holding Limited (NASDQQ: HUIZ)

    Keynote speaker: Mr. Ron Tam, Co CFO

    10:15 - 10:45

    Ascend Wellness Holdings Inc. (OTCQX:AAWH)

    Keynote speaker: Rebecca Koar, EVP of Investor Relations and Strategy

    10:50 – 11:20

    Targa Exploration Corp. (OTCQB:TRGEF) (CSE:TEX)

    Keynote speaker: Cameron Tymstra, President & CEO

    11:25 - 11:55

    Sucro Limited (TSXV:SUG) (OTCQB:SUGCF)

    Keynote speaker: Don Hill, Chairman

    12:00 – 12:30

    Patriot AG Corp.

    Keynote speaker: Eric Till, CEO / CFO, & Kyle Severson, COO

    12:35 – 1:05

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

    Keynote speaker: Jason Awe, Head of Corporate Communications & IR

    1:10 – 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    1:45 - 2:15

    InMed Pharmaceuticals, Inc. (NASDAQ:INM)

    Keynote speaker: Eric Adams, CEO

    2:20 – 2:30

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    2:35 - 2:45

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Gerald W. Shields, Vice Chairman and CEO Jeff Conklin, CFO

    2:50 – 3:00

    Digital Brand Media & Marketing Group, Inc. (OTC:DBMM)

    Keynote speaker: Reggie James, COO, Sr. VP & Exec. Director

    3:05 – 3:15

    ATRenew Inc. (NYSE:RERE)

    Keynote speakers: Jessie Jin, Investor Relations Manager & Jeremy Ji, Director of Corporate Development & Investor Relations

    3:20 - 3:30

    Meihua International Medical Technologies Co. (NASDAQ:MHUA)

    Keynote speaker: Mr. Steven Wang, CEO

    3:35 – 3:45

    GTI Energy, Ltd. (OTC:GTRIF) (ASX: GTR)

    Keynote speaker: Bruce Lane, Executive Director, CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: Conference@EmergingGrowth.com



    Primary Logo

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI
    $ATRA
    $CIA
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Unusual Machines Inc.
    $UMAC
    8/19/2025$15.00Buy
    Needham
    Unusual Machines Inc.
    $UMAC
    12/18/2024$18.00Buy
    Maxim Group
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Perfect Corp.
    $PERF
    10/21/2024$5.00Outperform
    Noble Capital Markets
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    Cadrenal Therapeutics Inc.
    $CVKD
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    YouCam Unveils Egg-citing 2026 Easter Digital Experiences with AI-Powered Creativity

    Bringing Spring to Life Through Playful Effects, Immersive Templates, and Generative AI Innovation in YouCam Makeup, YouCam Perfect, YouCam AI Pro, YouCam Enhance and YouCam Video Perfect Corp., the leading AI and AR beauty and fashion technology provider and developer of ‘Beautiful AI' solutions, is delighted to introduce its 2026 Easter digital content collection in the suite of YouCam apps through an imaginative and engaging set of seasonal experiences designed to inspire creativity and celebration across its global user community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402626972/en/YouCam Unveils Egg-citing 2026

    4/2/26 4:30:00 PM ET
    $PERF
    Computer Software: Prepackaged Software
    Technology

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

    PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal's first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administra

    3/31/26 8:45:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Needham initiated coverage on Unusual Machines with a new price target

    Needham initiated coverage of Unusual Machines with a rating of Buy and set a new price target of $15.00

    8/19/25 8:37:18 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASPI
    $ATRA
    $CIA
    $CLNN
    SEC Filings

    View All

    SEC Form D filed by Cadrenal Therapeutics Inc.

    D - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    4/6/26 4:05:26 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    4/3/26 4:19:20 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by InMed Pharmaceuticals Inc.

    424B5 - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    4/3/26 4:17:05 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ugwumba Chidozie

    4 - Clene Inc. (0001822791) (Issuer)

    4/6/26 5:32:25 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lehr Paul T

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/3/26 5:00:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Locklear Lisa

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/3/26 5:00:15 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Financials

    Live finance-specific insights

    View All

    Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

    PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal's first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administra

    3/31/26 8:45:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea

    3/25/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    ATRenew Inc. Announces Appointment of New Director

    SHANGHAI, March 6, 2026 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE:RERE), a pioneer in technology-driven recycling and trade-in solutions for consumer products in China, today announced that Mr. Yue Teng has been appointed as a new member of the Company's board of directors (the "Board") and the compensation committee of the Board, and Ms. Rui Zhu has been appointed as a new member of the nominating and corporate governance committee of the Board, effective immediately, to fill the vacancies arising from the resignation of Mr. Mervin Ye Zhou. Upon the appointment of Mr. Yue Teng, the Board consists of eight members: Mr. Kerry Xuefeng Chen, Mr. Yongliang Wang, Mr. Chen Ch

    3/6/26 3:00:00 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    Quantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer

    DALLAS, March 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Nate Salpeter, Ph.D. as its Chief Technology Officer. Dr. Salpeter is a recognized key opinion leader in the field of physics-constrained energy technology optimization, with more than 15 years of experience building computational frameworks, laser-based experimental methods, and first-of-kind engineering programs across nuclear energy and advanced thermal sys

    3/5/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Military UAV Sector Forecast to Surpass $40+ Billion as Modern Warfare Evolves

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense and military operations, reshaping strategies from reconnaissance to precision strike capabilities. Military drones offer armed forces enhanced situational awareness, reduced risk to personnel, and cost-efficient mission profiles across surveillance, target acquisition, logistics, and electronic warfare. As autonomous systems incorporating artificial intelligence and advanced sensor suites continue to mature, they are increasingly integral to networked battlefield operations and force multiplie

    2/19/26 8:30:00 AM ET
    $NOC
    $PRZO
    $UAVS
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical
    Aerospace

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials